Arjun Srinivasan, M.D., Carl N. Kraus, M.D., David DeShazer, Ph.D., Patrice M. Becker, M.D., James D. Dick, Ph.D., Lisa Spacek, M.D., John G. Bartlett, M.D., W. Russell Byrne, M.D., and David L. Thomas, M.D.
Infection with Burkholderia mallei (formerly Pseudomonas mallei)can cause a subcutaneous infection known as farcy or can disseminateto cause the condition known as glanders. In humans, acute infectionwith B. mallei is characterized by necrosis of the tracheobronchialtree, pustular skin lesions, and either a febrile pneumonia,if the organism was inhaled, or signs of sepsis and multipleabscesses, if the skin was the portal of entry.1 At the turnof the 20th century, glanders was an important cause of deathamong horses, and there were secondary, often fatal, infectionsin humans.2 Because of the lethal and contagious nature of thedisease, B. mallei was considered an ideal agent for biologicwarfare and was used for this purpose by Germany in World WarI.3
Aggressive control measures essentially eliminated glandersfrom the West. However, with the resurgent concern about biologicwarfare, B. mallei is now being studied in laboratories worldwide.We describe here the first reported case of human glanders inthe United States in more than 50 years and discuss some ofthe important events in the history of the disease and its initialeradication.
Case Report
In March 2000, tender, left axillary adenopathy and fever (temperature,38.6°C) developed in a 33-year-old microbiologist at theU.S. Army Medical Research Institute for Infectious Diseaseswho had type 1 diabetes mellitus. The patient had worked fortwo years investigating the basic microbiology of B. malleiand did not routinely wear latex gloves. The adenopathy andfever persisted despite treatment for 10 days with a first-generationcephalosporin. An evaluation after this treatment, which includedchest radiography as well as cultures of blood and urine, wasunrevealing. During the next few weeks, the patient had increasingfatigue, night sweats, malaise, rigors, and weight loss.
In early April, his symptoms and adenopathy resolved duringa 10-day course of clarithromycin, but he relapsed 4 days afterthe medication was stopped. On May 2, he was admitted to hislocal hospital with diabetic ketoacidosis. A computed tomographic(CT) scan showed multiple hepatic and splenic abscesses (Figure 1A).On May 4, respiratory distress requiring mechanical ventilationdeveloped, and the patient was transferred to Johns HopkinsHospital in Baltimore.
Figure 1. Pretreatment (Panel A) and Post-Treatment (Panel B) Abdominal Computed Tomographic Scans from a Patient with Glanders.
Panel A shows multiple hepatic and splenic abscesses (arrows), and Panel B shows nearly complete resolution of the abscesses.
Physical examination revealed a temperature of 40.3°C anda heart rate of 122 beats per minute. The patient had a grade2/6 systolic murmur, coarse breath sounds, and moderate epigastrictenderness. Laboratory studies showed a white-cell count of8300 per cubic millimeter, with 83 percent neutrophils, 9 percentmonocytes, and 8 percent lymphocytes. The hematocrit was 25.6percent. The concentrations of aspartate aminotransferase andalanine aminotransferase were 53 U per liter and 56 U per liter,respectively, and the alkaline phosphatase was 197 IU per liter.Cultures of the patient's blood and a sample from a fine-needleaspiration biopsy of a liver abscess grew a small, bipolar,weakly staining, gram-negative rod that was identified by anautomated bacterial-identification system as Pseudomonas fluorescensor P. putida. However, gasliquid chromatography of thecellular fatty acids (Microbial ID, Newark, Del.) placed theorganism in the genus burkholderia. Subsequent phenotypic testingand 16S ribosomal RNA gene-sequence analysis identified theorganism as B. mallei (Figure 2). Initial susceptibility testingshowed the isolate to be sensitive to imipenem, ceftazidime,and tetracycline.
Figure 2. Phylogenetic Tree Derived from 1.5-kb Nucleotide Sequences of 16S Ribosomal RNA from the Infecting Organism and Other Related Isolates from the Johns Hopkins Microbiology Laboratory and GenBank.
The tree was constructed on the basis of neighbor-joining (N join) analysis. Pseudomonas aeruginosa was used as an outgroup. Numbers beside strains are the American Type Culture Collection reference numbers of the strains we sequenced. The genetic distance between two species is obtained by adding the lengths of the connecting horizontal lines. The length of the bar at the top denotes a sequence divergence of 9.996 percent.
The patient was treated with imipenem and doxycycline, and therewas rapid improvement. After two weeks, the imipenem was replacedby azithromycin, and the patient completed a six-month courseof treatment with azithromycin and doxycycline. Although theorganism was found retrospectively to be relatively resistantto azithromycin, a CT scan obtained after six months of treatmentshowed substantial improvement of the liver and spleen abscesses(Figure 1B), and one year later the patient remained in goodhealth.
Discussion
This is the first reported human case of glanders in the English-languagemedical literature since 1949,4 and it occurred in the contextof research on agents of biologic warfare.
Glanders may have been the first biologic weapon of the 20thcentury. During World War I, Germany had a program of biologicsabotage against several countries, including the United States,whereby cultures of B. mallei and anthrax were distributed toundercover agents who attempted to infect livestock that wereto be shipped to Allied countries.3 The intention was both thedestruction of livestock and the transmission of the highlycontagious, lethal agent from livestock to humans. It is currentlysuspected that attempts are being made to develop an aerosolizedform of antibiotic-resistant B. mallei that could become a biologicweapon as potent as anthrax.
Glanders, an important human and veterinary disease, was eliminatedwithout a vaccine or effective treatment. It appears to havebeen abolished by the veterinary use of a skin test to detectexposure to B. mallei combined with draconian agricultural measuresto control infection.5
At the turn of the 20th century, Canada, Britain, and the UnitedStates all implemented glanders-control programs. By that time,the symptoms of equine glanders, which include fever and inflammationof the nasal mucosa with ultimate necrosis and obstruction ofthe oropharynx, had been well described.6 Laws were passed thatrequired notification of the health department and the immediateslaughter of affected animals, with proper disposal of the carcasses.In addition, all horses on the premises where the infected horseswere found had to be tested with the mallein skin test for exposureto B. mallei; any horses with a reaction also had to be slaughtered.Horses with no reaction were quarantined and then retested twoto three weeks later. Furthermore, the equine contacts of thehorses were traced to track down other horses that might havebeen exposed and then moved to other facilities.
The case we describe illustrates the major clinical featuresof glanders, which can usually be traced to direct contact withB. mallei, as in workers exposed to animals with glanders7 andin personnel who were exposed in laboratories during World WarII.8 Although the patient discussed here could not recall aclear break in his skin or an accident in the laboratory, mostreported occupational infections occur without recognized instancesof exposure.9 As Robins commented in 1906, "It is perhaps notadvisable to be too dogmatic as to the invariable necessityof an abrasion being present in every case of human glanders. . . [as] in several such cases of our series it is distinctlystated that there was no abrasion."7 As in our patient, B. malleioften enters the body through the hand or arm. After an incubationperiod lasting between a few days and several weeks, local suppurationand regional lymphadenopathy occur. Constitutional symptomsoften accompany the infection, with fever, rigors, and malaisepredominating. If the infection is left untreated, abscessesin the lymph nodes will generally form, then break down anddrain.
Dissemination of the infection occurs one to four weeks afterinfection of the lymph nodes. Abscesses can be widespread, andB. mallei can infect almost any tissue.7 Abscesses in the liverand the spleen, as were seen in our patient, appear to be relativelycommon, as does pulmonary involvement, including consolidation,abscesses, and pleural nodules. The acute onset and rapid resolutionof the respiratory failure in our patient were more consistentwith the respiratory distress syndrome associated with gram-negativebacteremia than with that associated with pulmonary glanders.Subcutaneous and intramuscular abscesses sometimes develop aswell.7
There are few data regarding the antibiotic treatment of glanders,since the disease had largely disappeared by the time antibioticsbecame available. In vitro, ceftazidime, gentamicin, imipenem,doxycycline, and ciprofloxacin all have reliable activity againstB. mallei,10 and our patient's infection responded well to acombination of imipenem and doxycycline. Experimentally inducedglanders also responds to a combination of sulfazine and trimethoprim.11However, treatment of the disease in the setting of bioterrorismmay be more difficult if the organism is drug-resistant.
This case demonstrates the difficulties that microbiology laboratoriesmay have in recognizing potential agents of biologic warfare.These microbes are rarely encountered and may be misidentifiedby conventional, phenotypic identification systems. Techniquessuch as cellular analysis of fatty acid and 16S ribosomal RNAgene sequencing can be used to identify the organisms correctly,but these tests are not widely available.
Finally, this case may serve as a harbinger of the resurgenceof nearly forgotten diseases such as glanders, plague, smallpox,and anthrax. Research on these diseases is now being conductedin more laboratories, which increases the risk of occupationalexposure. There is also the looming threat that some group willeventually mount a successful campaign of bioterrorism. Resourcesmust be allocated both to prevent and to prepare for these frighteningpossibilities.
We are indebted to John Bartel of MIDI for assistance with dataanalysis and to Joan Valentine for 16S ribosomal RNA gene sequencing.
Source Information
From the Division of Infectious Diseases (A.S., L.S., J.G.B., D.L.T.), the Division of Pulmonary and Critical Care Medicine (P.M.B.), and the Department of Pathology (J.D.D.), Johns Hopkins Medical Institutions, Baltimore; the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. (C.N.K.); and the U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Md. (D.D., W.R.B.).
Address reprint requests to Dr. Thomas at 424 N. Bond St., Baltimore, MD 21231.
Wilkinson L. Glanders: medicine and veterinary medicine in common pursuit of a contagious disease. Med Hist 1981;25:363-384. [Medline]
Wheelis M. First shots fired in biological warfare. Nature 1998;395:213-213. [Medline]
Womack CR, Wells EB. Co-existent chronic glanders and multiple cystic osseous tuberculosis treated with streptomycin. Am J Med 1949;6:267-271. [Medline]
McGilvray CD. The transmission of glanders from horse to man. Can J Public Health 1944;35:268-275.
Dunlop RH, Williams DJ, eds. Veterinary medicine: an illustrated history. St. Louis: Mosby, 1996:456-7.
Robins GD. A study of chronic glanders in man with report of a case: analysis of 156 cases collected from the literature. Stud R Victoria Hosp Montreal 1906;2(1):1-98.
Biological and chemical terrorism: strategic plan for preparedness and response: recommendations of the CDC Strategic Planning Workgroup. MMWR Morb Mortal Wkly Rep 2000;49:1-14. [Medline]
Vesley D, Hartmann HM. Laboratory-acquired infections and injuries in clinical laboratories: a 1986 survey. Am J Public Health 1988;78:1213-1215. [Free Full Text]
Kenny DJ, Russell P, Rogers D, Eley SM, Titball RW. In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp. Antimicrob Agents Chemother 1999;43:2773-2775. [Free Full Text]
Batmanov VP. Treatment of experimental glanders with combinations of sulfazine or sulfamonomethoxine with trimethoprim. Antibiot Khimioter 1993;38:18-22. [Medline]
Whitlock, G. C., Valbuena, G. A., Popov, V. L., Judy, B. M., Estes, D. M., Torres, A. G.
(2009). Burkholderia mallei cellular interactions in a respiratory cell model. J Med Microbiol
58: 554-562
[Abstract][Full Text]
Goodyear, A., Kellihan, L., Bielefeldt-Ohmann, H., Troyer, R., Propst, K., Dow, S.
(2009). Protection from Pneumonic Infection with Burkholderia Species by Inhalational Immunotherapy. Infect. Immun.
77: 1579-1588
[Abstract][Full Text]
Kimman, T. G., Smit, E., Klein, M. R.
(2008). Evidence-Based Biosafety: a Review of the Principles and Effectiveness of Microbiological Containment Measures. Clin. Microbiol. Rev.
21: 403-425
[Abstract][Full Text]
Fernandes, P. J., Guo, Q., Waag, D. M., Donnenberg, M. S.
(2007). The Type IV Pilin of Burkholderia mallei Is Highly Immunogenic but Fails To Protect against Lethal Aerosol Challenge in a Murine Model. Infect. Immun.
75: 3027-3032
[Abstract][Full Text]
Rowland, C. A., Lertmemongkolchai, G., Bancroft, A., Haque, A., Lever, M. S., Griffin, K. F., Jackson, M. C., Nelson, M., O'Garra, A., Grencis, R., Bancroft, G. J., Lukaszewski, R. A.
(2006). Critical Role of Type 1 Cytokines in Controlling Initial Infection with Burkholderia mallei. Infect. Immun.
74: 5333-5340
[Abstract][Full Text]
Ulrich, M. P., Norwood, D. A., Christensen, D. R., Ulrich, R. L.
(2006). Using real-time PCR to specifically detect Burkholderia mallei.. J Med Microbiol
55: 551-559
[Abstract][Full Text]
Tomaso, H., Scholz, H. C., Al Dahouk, S., Eickhoff, M., Treu, T. M., Wernery, R., Wernery, U., Neubauer, H.
(2006). Development of a 5'-Nuclease Real-Time PCR Assay Targeting fliP for the Rapid Identification of Burkholderia mallei in Clinical Samples. Clin. Chem.
52: 307-310
[Abstract][Full Text]
Lim, D. V., Simpson, J. M., Kearns, E. A., Kramer, M. F.
(2005). Current and Developing Technologies for Monitoring Agents of Bioterrorism and Biowarfare. Clin. Microbiol. Rev.
18: 583-607
[Abstract][Full Text]
Glass, M. B., Popovic, T.
(2005). Preliminary Evaluation of the API 20NE and RapID NF Plus Systems for Rapid Identification of Burkholderia pseudomallei and B. mallei. J. Clin. Microbiol.
43: 479-483
[Abstract][Full Text]
Nierman, W. C., DeShazer, D., Kim, H. S., Tettelin, H., Nelson, K. E., Feldblyum, T., Ulrich, R. L., Ronning, C. M., Brinkac, L. M., Daugherty, S. C., Davidsen, T. D., Deboy, R. T., Dimitrov, G., Dodson, R. J., Durkin, A. S., Gwinn, M. L., Haft, D. H., Khouri, H., Kolonay, J. F., Madupu, R., Mohammoud, Y., Nelson, W. C., Radune, D., Romero, C. M., Sarria, S., Selengut, J., Shamblin, C., Sullivan, S. A., White, O., Yu, Y., Zafar, N., Zhou, L., Fraser, C. M.
(2004). From the Cover: Structural flexibility in the Burkholderia mallei genome. Proc. Natl. Acad. Sci. USA
101: 14246-14251
[Abstract][Full Text]
Shapiro, D. S.
(2003). Surge Capacity for Response to Bioterrorism in Hospital Clinical Microbiology Laboratories. J. Clin. Microbiol.
41: 5372-5376
[Abstract][Full Text]
Lever, M. S., Nelson, M., Ireland, P. I., Stagg, A. J., Beedham, R. J., Hall, G. A., Knight, G., Titball, R. W.
(2003). Experimental aerogenic Burkholderia mallei (glanders) infection in the BALB/c mouse. J Med Microbiol
52: 1109-1115
[Abstract][Full Text]
Gee, J. E., Sacchi, C. T., Glass, M. B., De, B. K., Weyant, R. S., Levett, P. N., Whitney, A. M., Hoffmaster, A. R., Popovic, T.
(2003). Use of 16S rRNA Gene Sequencing for Rapid Identification and Differentiation of Burkholderia pseudomallei and B. mallei. J. Clin. Microbiol.
41: 4647-4654
[Abstract][Full Text]
Ramisse, V., Balandreau, J., Thibault, F., Vidal, D., Vergnaud, G., Normand, P.
(2003). DNA-DNA hybridization study of Burkholderia species using genomic DNA macro-array analysis coupled to reverse genome probing. Int. J. Syst. Evol. Microbiol.
53: 739-746
[Abstract][Full Text]
Deitchman, S., Sokas, R., Srinivasan, A., Thomas, D., DeShazer, D.
(2001). Glanders in a Military Research Microbiologist. NEJM
345: 1644-1644
[Full Text]
Cohen, H. W., Sidel, V. W., Gould, R. M.
(2001). Preparedness for Bioterrorism?. NEJM
345: 1423-1424
[Full Text]
Khan, A. S., Ashford, D. A.
(2001). Ready or Not -- Preparedness for Bioterrorism. NEJM
345: 287-289
[Full Text]